General MedicationsINTRAVENOUSGeneric

FUSILEV

LEVOLEUCOVORIN CALCIUM

Standard Dose

EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview FUSILEV is listed in Drugs@FDA under application 020140 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOLEUCOVORIN CALCIUM Form and strength SOLUTION;INTRAVENOUS - EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-11-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview FUSILEV is listed in Drugs@FDA under application 020140 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LEVOLEUCOVORIN CALCIUM Form and strength SOLUTION;INTRAVENOUS - EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ACROTECH BIOPHARMA Submission history Latest submission status date: 2020-11-23 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.